Mylan's Copaxone copy could face another hold-up with FDA info request
admin 16th June 2017 Uncategorised 0Mylan’s long-delayed Copaxone generic may be delayed even longer. Wednesday at the Goldman Sachs annual healthcare conference, company CEO Heather Bresch acknowledged that Mylan had recently received an “information request” from the FDA over its knockoff of Teva’s 20 mg multiple sclerosis blockbuster.
More: Mylan's Copaxone copy could face another hold-up with FDA info request
Source: fierce